Article Text

PDF
Commentary on “Immunosuppressant drugs for myasthenia gravis”
  1. Maria Grazia Celani,
  2. Peter Sandercock,
  3. Graeme Hankey,
  4. Cochrane Neurological Network
  1. Dr Maria Grazia Celani, Dipartimento di medicina Servizio per le Mt Cerebrovascolari via Guerra 17, 06127 Perugia, Italy; mgcelani{at}iol.it

Statistics from Altmetric.com

The choice of treatments for this chronic, disabling yet rare disorder is limited and founded on a weak evidence base. The conclusion that corticosteroid treatment offers significant short-term benefit is based on sources of evidence …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Cochrane neurological network corner
    I K Hart T Sharshar S Sathasivam